The combination of polymyxin B and rifampin resulted in an additive effect against all 12 clinical isolates of Serratia marcescens examined, including multiple-drug-resistant isolates.
(ii) Media. Brain heart infusion agar and broth, tryptic soy broth, and Mueller-Hinton agar and broth were purchased from Difco Laboratories, Detroit, Mich. The organisms were maintained on brain heart infusion agar slants at 4 C, and in a mixture of 1 volume of brain heart infusion broth plus 1 volume of heat-inactivated bovine serum (Behringwerke, Marburg, Germany) at -65 C.
(iii) Antibiotics. Rifampin (lot no. 9124) was a gift from Ciba-Geigy AG, Wehr/Baden, Germany; stock solutions (2,000 zg/ml) were prepared in 20 vol% of aqueous methanol, membrane filter sterilized, and stored at 4 C in the dark. Amikacin (BB-K8) was obtained through the courtesy of Bristol Laboratories, Syracuse, N.Y. (lot no. 74F 1805); polymyxin B was a gift from Pfizer GmbH, Karlsruhe, Germany (no lot number given). Aqueous stock solutions of the latter two drugs (2,000 gg/ml) were filter sterilized and stored in small aliquots at -65 C. Antibiotic "high content" disks were procured from Difco.
(iv) Antibiotic susceptibility tests. Disk susceptibility tests were carried out in accordance with the technique of Bauer et al. (1). Minimal inhibitory concentrations of rifampin, polymyxin B, and amikacin were determined in a microtiter system (Cooke Engineering Co., Alexandria, Va.). The antibiotic master dilutions had been prepared conventionally in Mueller-Hinton broth and were delivered with dropper pipettes (0.05 ml). Bacterial inocula (0.05 ml) were adjusted to yield a final number of 1.5 x 106 colony-forming units/ml at 0 time (10) . The combined activity of polymyxin B and rifampin likewise was examined in the microtiter system; U-shaped wells received 0.05 ml of each respective 4x antibiotic dilution or Mueller-Hinton broth (control) and 2 x 0.05 ml of the adjusted bacterial inoculum. Thus, We have no explanation for the fact that the combination of polymyxin B (biochemical target: cell wall/lipopolysaccharide and cytoplasmic membrane) and rifampin (biochemical target: deoxyribonucleic acid-dependent ribonucleic acid polymerase) proved additively effective against all isolates of S. marcescens tested. Possibly polymyxin B in some way or another facilitates the uptake of rifampin, thus accounting for the observed additive effect. It is known that the former drug interacts with the cell wall of S. marcescens, rendering exposed cells transiently bile-salt susceptible (Traub and Kleber, in press) and removing, though incompletely, lipopolysaccharide receptors for group A (phage tail) bacteriocins (9) . The observed effect is reminiscent of the previously demonstrated additive effect of sulfonamides and polymyxin B against isolates of Proteus (7) and S. marcescens (4) . In any case, the results confirm the original observation of Perez Urena and co-workers (5). It may be added that polymyxin B and rifampin also resulted in an additive effect against our previously characterized (8), lactose-fermenting, multiple-drug-resistant strain of Proteus rettgeri (unpublished data). 
